 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "AM-7438" – news ·newspapers ·books ·scholar ·JSTOR(February 2026) |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H31NO4 |
| Molar mass | 397.515 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AM-7438 is a drug which is acannabinoid receptor agonist, developed by the research team led by DrAlexandros Makriyannis. It is a derivative of Δ8-THC which has been substituted with a side chain containing a metabolically labileester group, allowing the molecule to be rapidly metabolised to an inactive form, in a similar manner to drugs such asremifentanil,remimazolam andSN 35210. This means that while AM-7438 retains potent cannabinoid effects, it has a much shorter duration of action than most related compounds.[1]
